Clinical trials: Nutrition Assessment
Overweight and/or Obesity, Weight Management
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity
- Trial name
- NCT07243171
- Testing
- ecnoglutide tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Obesity, Obesity, Abdominal
Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate in the evaluation of their medical management.
- Conditions
- Obesity, Obesity, Abdominal, Obesity, Visceral, Female
- Trial name
- PPAR-NAPAS (NCT04436419)
- Testing
- Alpha lipoic acid (plus full hospitalization)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Fauqué
HIV, Malnutrition
Study of Impacts of Food Supplementation on Malnourished HIV-Infected Adults in Kenya
The purpose of the study is to test whether food supplementation of malnourished HIV-infected adults (both pre-ART and ART) in resource constrained settings improves their nutritional status, clinical status, effectiveness of…
- Conditions
- HIV, Malnutrition, HIV Infections
- Trial name
- NCT00838292
- Testing
- fortified blended flour - Insta Foundation Plus (with whey protein concentrate), nutrition counseling
- Where
- 6 sites in Kenya
- Volunteers
- 1,049 people
- Sponsor
- Academy for Educational Development
Overweight
Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants
The purpose of this study is to evaluate the effects of RM-493 on mean percent body weight loss, and other weight loss parameters as well as Pharmacokinetic (PK) profile, and ambulatory blood pressure in obese participants.
- Trial name
- NCT01749137
- Testing
- Setmelanotide
- Where
- 6 sites in United States
- Volunteers
- 74 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Overweight, Obesity
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity
This study is open to adults with overweight or obesity who are otherwise healthy. People can join the study if they have a body mass index of 27 to 39.9 kg/m2 and a body weight over 70 kg.
- Trial name
- NCT06564441
- Testing
- Survodutide, Bupropion, Caffeine
- Where
- Belgium
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Cardiovascular Disease, Diabetes
Diet and Activity Promotion Among Older Working Adults
The trial will test whether the Alive email-delivered health behavior program can improve subjects' physical activity, fruits and vegetables and saturated/trans fats and added sugars.
- Conditions
- Cardiovascular Disease, Diabetes, Obesity, Aging
- Trial name
- ALIVE (NCT01233063)
- Testing
- Physical Activity and Diet Intervention via Alive2
- Where
- United States
- Volunteers
- 610 people, healthy volunteers welcome
- Sponsor
- Berkeley Analytics, Inc.
Enteral Nutrition
Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG)
This is a Multicenter, Open-label, Single-arm study evaluating the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG) in the Nutritional Management of Tube-fed Children Aged 1-4…
- Trial name
- NCT04516213
- Testing
- Enteral Formula With (PHGG)
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Société des Produits Nestlé (SPN)
Obesity
Pilot Study to Evaluate A Novel Gastric Space Occupying Device
This will be an observational, prospective, non-randomized, pilot study to gain initial device experience on a novel space-occupying device in persons who are overweight or obese. No formal hypothesis testing will be conducted.
- Trial name
- NCT01444274
- Testing
- Obalon Gastric Balloon(s)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Obalon Therapeutics, Inc.
Overweight or Obesity
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
This Phase I, active-controlled, randomised trial will be conducted in 2 parts. Part I aims to confirm the PD equivalence of EMP22 and Xenical® based on percent fecal fat excretion at steady state.
- Trial name
- NCT06013163
- Testing
- Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical®
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Empros Pharma AB
Malnutrition
Tolerance and Acceptability Evaluation AYMES Cardiff
To evaluate tolerance and acceptability of 'CARDIFF' in patients requiring supplementary oral nutritional support compared with currently available alternatives.
- Trial name
- NCT04703894
- Testing
- AYMES 'CARDIFF'
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Aymes International Limited
Obesity, Type 2 Diabetes
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adult subjects with type 2 diabetes mellitus.
- Trial name
- NCT02324491
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 16 sites in Australia
- Volunteers
- 152 people
- Sponsor
- Zafgen, Inc.
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 686 sites in United States, Argentina and 33 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Prader-Willi Syndrome
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
RGH-706 is a novel, potent, and orally active MCHR1 antagonist drug candidate discovered and being developed by Gedeon Richter Plc. for weight management.
- Trial name
- NCT05322096
- Testing
- RGH-706
- Where
- 23 sites in United States, Czechia and 3 more
- Volunteers
- 39 people
- Sponsor
- Gedeon Richter Plc.
Overweight, Obesity
A Research Study on How a Dose of NNC0662-0419 Works in Japanese, Chinese and Non-Asian Participants Living With Overweight or Obesity
The study is testing the new medicine NNC0662-0419 in people living with overweight or obesity. The purpose of the study is to look into the amount of the new medicine NNC0662-0419 in participants blood after one dose.
- Trial name
- NCT07101783
- Testing
- NNC0662-0419
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Novo Nordisk A/S
Complex Conditions, Including Impairment of the GI Tract
Neocate In Infants and Children With Complex Conditions
Infants and young children up to 10 years of age with a complex condition involving the gastrointestinal tract are at risk of poor nutritional status, including faltering growth.
- Trial name
- NICC (NCT04265729)
- Testing
- Neocate Infant and Junior marketed products
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 13 people
- Sponsor
- Nutricia Research
Low Muscle Strength, Malnutrition
Efficacy of Oral Nutritional Supplement in Community-Dwelling Adults Following Acute Care
The study aims to determine the effects of Oral Nutritional Supplement (ONS) added to usual care on body weight compared with usual care alone in community-dwelling adults aged 55 years and older who are at risk of malnutrition…
- Trial name
- NCT07753239
- Testing
- ONS, Standard of Care (SOC)
- Where
- 7 sites in Thailand
- Volunteers
- 304 people
- Sponsor
- Abbott Nutrition
Overweight , Obesity
Study of UBT37034 Injection
This is a study of UBT37034 for injection in participants who have obesity or are overweight. The main purpose is to learn more about the safety, tolerability, drug concentration, drug action and immune response of repeated…
- Trial name
- NCT07873645
- Testing
- UBT37034
- Volunteers
- 40 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Obesity
A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.
- Trial name
- NCT00131404
- Testing
- taranabant
- Volunteers
- 2,400 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Impact of Body Composition and Exercise on Clinical, Metabolic and Molecular Parameters in Type 2 Diabetics in Qatar
The prevalence of type 2 diabetes (T2DM) is increasing sharply around the world and obesity and sedentary lifestyles are driving the epidemic. Obesity is often, but not always present in patients with T2DM.
- Trial name
- NCT04081064
- Testing
- 10-week exercise programme based on aerobic interval and resistance training
- Where
- Qatar
- Volunteers
- 60 people
- Sponsor
- Hamad Medical Corporation
X-linked Hypophosphatemia (XLH)
Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH
The purpose of this study is to assess the safety, pharmacokinetics and efficacy of KRN23 in pediatric Chinese patients with XLH
- Trial name
- NCT04842032
- Testing
- KRN23
- Where
- 5 sites in China
- Volunteers
- 28 people
- Sponsor
- Kyowa Kirin Co., Ltd.